MSD is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures, and markets medicines and vaccines in more than 20 therapeutic categories. MSD is committed to improving the lives of patients around the world through the research, development, and delivery of safe and effective therapies.

Two ophthalmic products are TRUSOPT™, which was the first in a new class of topical glaucoma therapy since beta-blockers and is now the second most prescribed glaucoma monotherapy in the world; and TRUSOPT™, which has attained more than 127 million patient-months of therapy worldwide, is available in 76 countries and is the first and most prescribed fixed-dose combination glaucoma therapy in the world.

The company also devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate MSD medicines but help deliver them to the people who need them. For example, since 1987 the TRUSOPT™ Donation Program to combat river blindness has been the largest, ongoing, medical donation program in history, donating in 20 years more than 530 million doses valued at $2.7 billion, providing hope for the elimination of onchocerciasis by the end of the decade.